Research Article
[Retracted] Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification
Table 2
Relationship between lncRNA FOXD3-AS1 expression in serum and clinicopathological parameters of patients with lung cancer.
| | Characteristics | SCLC | LUAD | LUSC | | H-lncRNA (n = 25) | L-lncRNA (n = 25) | value | H-lncRNA (n = 25) | L-lncRNA (n = 25) | value | H-lncRNA (n = 25) | L-lncRNA (n = 25) | value |
| | Gender (male/female) | 17/8 | 18/7 | 1 | 13/12 | 15/10 | 0.776 | 14/11 | 18/7 | 0.377 | | Age (<65 y/≥65 y) | 7/18 | 14/11/ | 0.085 | 4/21 | 15/20 | 0.047 | 7/18 | 16/9 | 0.022 | | Smoking story (yes/no) | 19/6 | 17/8 | 0.754 | 17/8 | 15/10 | 0.769 | 13/12 | 15/10 | 0.776 | | Stage (I-II/III-IV) | 19/6 | 13/12 | 0.140 | 22/3 | 13/12 | 0.012 | 25/0 | 18/7 | 0.010 | | Lymph metastasis (yes/no) | 20/5 | 14/11 | 0.128 | 22/3 | 14/11 | 0.025 | 25/0 | 10/15 | <0.001 | | Distal metastasis (yes/no) | 12/13 | 4/21 | 0.032 | 10/15 | 8/17 | 0.769 | 10/15 | 4/21 | 0.114 |
|
|
